Carol Gallagher

Carol Gallagher is a Partner at NEA, joining in October, 2014. Carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Carol was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. Prior to Calistoga she served in various leadership roles at both large pharma and small biotech. In addition to serving as a director at Chromacode, she serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, PIONYR Immunotherapeutics, XOC, and Qpex.